Form 4: Phreesia SVP, Life Sciences, David Linetsky, Executes Stock Sale Under 10b5-1 Plan

David Linetsky, SVP of Life Sciences at Phreesia, sold 500 shares of common stock at an average price of $29.682, as part of a pre-arranged trading plan.

Summary

• David Linetsky, Senior Vice President of Life Sciences at Phreesia, sold 500 shares of common stock on January 29, 2025.
• The sale was executed at a weighted average price of $29.682 per share.
• The transactions occurred within a price range of $29.595 to $29.88 per share.
• This sale was conducted under a pre-arranged Rule 10b5-1 trading plan adopted on July 18, 2024.
• Following the transaction, Mr. Linetsky directly owns 230,771 shares of Phreesia common stock and indirectly owns 8,851 shares through his spouse.

Sentiment

Score: 5

Explanation: The document reflects a routine stock sale by an executive under a pre-arranged plan, which is neither positive nor negative for the company's overall outlook.

Industry Context

This is a routine filing related to insider trading activity. It is common for executives to use 10b5-1 plans to manage their stock sales to avoid accusations of insider trading.

Comparison to Industry Standards

• The use of 10b5-1 trading plans is a common practice among executives at publicly traded companies to manage their stock sales.
• The reported price range and average price are within the expected fluctuations for a stock like Phreesia.
• Similar filings are regularly made by executives at comparable companies such as Veeva Systems and Allscripts Healthcare Solutions.

Stakeholder Impact

• The stock sale by an executive may have a minor impact on shareholder sentiment, but is unlikely to significantly affect the company's overall performance.

Key Dates

Keywords

Phreesia, David Linetsky, stock sale, Rule 10b5-1, insider trading, equity securities, SVP Life Sciences